维立西呱治疗心力衰竭的作用机制及研究进展
Mechanism of action and research progress of vericiguat in treatment of heart failure
佘林聪 1方业贤 1王家欣 1冯艳 1陈江红 1张薇1
作者信息
- 1. 空军军医大学第二附属医院心血管内科,陕西西安 710038
- 折叠
摘要
心力衰竭(心衰)因其复杂的发病机制和缺乏有效的治疗方案成为目前医学领域的研究难点.NO-sGC-cGMP通路是一条与心血管疾病密切相关的、高度保守的信号通路.维立西呱是心衰治疗领域针对NO-sGC-cGMP通路首次取得阳性结果的药物,为心衰的临床治疗带来新角度、新思路.本文将简述基于该途径研发的可溶性鸟苷酸环化酶激动剂维立西呱在心衰领域的研究进展,对维立西呱治疗心衰的作用机制、临床前研究、临床研究以及在我国的进展情况进行综述,以期为临床合理用药提供帮助.
Abstract
Heart failure,as a common,incurable and life-threatening condition,is a fortress we have yet to conquer.The NO-sGC-cGMP pathway plays an important role in endothelial function and myocardial energy metabolism.Vericiguat is the first drug in the field of heart failure that has achieved positive results for this pathway,providing new perspectives and methods for clinical treatment of heart failure.In this paper,the research progress of soluble guanylate cyclase agonist vericiguat in the field of heart failure was reviewed,including the mechanism of action of vericiguat in the treatment of heart failure,preclinical studies,clinical studies and its progress in China,with the aim for rational clinical administration of vericiguat.
关键词
维立西呱/可溶性鸟苷酸环化酶激动剂/心力衰竭Key words
vericiguat/soluble guanylate cyclase/heart Failure引用本文复制引用
出版年
2024
NETL
NSTL
万方数据